1994
DOI: 10.1111/j.1472-8206.1994.tb00783.x
|View full text |Cite
|
Sign up to set email alerts
|

Systemic, regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers

Abstract: The effects of two single oral doses (5 mg and 20 mg) of a new angiotensin I-converting enzyme inhibitor, imidapril, on a) systemic hemodynamics (arterial pressure, heart rate, cardiac output), b) brachial and common carotid arteries' hemodynamics (diameter and blood flow, pulsed Doppler technique), c) cerebral hemodynamics (middle cerebral artery mean blood flow velocity, transcranial Doppler technique), and d) biological parameters (plasma converting enzyme activity, active plasma renin, plasma aldosterone, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

1997
1997
2001
2001

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 10 publications
(4 citation statements)
references
References 21 publications
(14 reference statements)
0
4
0
Order By: Relevance
“…Effective renal blood flow increased significantly only in patients treated with spirapril, and not in those treated with captopril, and there were no changes in hepatic blood flow or cerebral blood flow [43]. Others have found no significant increase in brachial artery flow with ACE inhibition [44,45]. It has been documented that an ACE inhibitor can reduce basal and post-exercise limb blood flow in humans [46].…”
Section: Discussionmentioning
confidence: 98%
“…Effective renal blood flow increased significantly only in patients treated with spirapril, and not in those treated with captopril, and there were no changes in hepatic blood flow or cerebral blood flow [43]. Others have found no significant increase in brachial artery flow with ACE inhibition [44,45]. It has been documented that an ACE inhibitor can reduce basal and post-exercise limb blood flow in humans [46].…”
Section: Discussionmentioning
confidence: 98%
“…Although there is little doubt that, when infused directly into an artery, ACE inhibitors and their precursors cause arteriolar vasodilatation, systemic administration of an ACE inhibitor does not necessarily have the same effect, because a decrease in blood pressure will tend to reduce blood flow while vasodilatation will tend to increase blood flow, i.e. Others have found no significant increase in brachial artery flow with ACE inhibition [44,45]. This may be why oral ACE inhibition did not alter cerebral blood flow in one study [41], but lowered cerebral blood flow in another [42].…”
Section: Discussionmentioning
confidence: 99%
“…Imidapril is an angiotensin converting enzyme (ACE) inhibitor without an SH‐group, currently under investigation for treatment of hypertension and congestive heart failure (CHF) [1–3]. Imidapril is a prodrug, its active metabolite imidaprilat is generated in the liver after hydroxylation and eliminated via the kidneys [4].…”
Section: Introductionmentioning
confidence: 99%
“…About 40% of the drug is absorbed after oral administration [4]. In healthy volunteers, imidapril, 10 mg once daily, resulted in 85–90% inhibition of plasma ACE [1, 3]. In patients with mild to moderate hypertension the same dose of 10 mg once daily has induced sustained reduction of blood pressure in about 60% of treated patients.…”
Section: Introductionmentioning
confidence: 99%